|
Fig. 6 Proteomic analysis reveals upregulation of the Protein Kinase A and AMPK signaling pathway with SB treatment. (A) Ingenuity pathway analysis (IPA) predicted activation of the Protein Kinase A and AMPK signaling pathway upon SB treatment on ataxin-3-84Q expressing SH-SY5Y cells. Blue indicates IPA predicted an inhibition versus orange refers to an activation. (B) Immunoblots of ataxin-3-84Q zebrafish protein samples treated with SB or a vehicle control. Blots were probed with AMPK, phosphorylated ULK1 (Ser777) and ULK1. (C) Quantification revealed increased AMPK levels with SB treatment compared to vehicle-treated (p = .0209, n = 8). (D) Densitometric analysis revealed an increased pULK1/ULK1 ratio in the SB treatment compared to the vehicle-treated SCA3 zebrafish (p = .0469, n = 7). Quantification of ULK1 revealed increased ULK1 protein at 120 kDa relative to total ULK1 and decreased 110 kDa relative to total ULK1 in SB-treated SCA3 zebrafish compared to the vehicle control (p = .0078 and p = .0156, respectively; n = 8). Data represent mean ± SEM. Statistical analysis performed was a paired non-parametric t-test (Wilcoxon test). *p < 0.05, **p < 0.01.